From: The effect of dapagliflozin treatment on epicardial adipose tissue volume
 | Dapagliflozin (N = 20) | Conventional therapy (N = 20) | p value |
---|---|---|---|
Age (years) | 68 ± 4 | 66 ± 6 | 0.30 |
Male/female (n) | 16/4 | 14/6 | 0.48 |
Body weight (kg) | 71.4 ± 14.4 | 69.5 ± 12.2 | 0.37 |
BMI | 26.6 ± 4.6 | 25.0 ± 3.1 | 0.25 |
Hypertension | 14 (70) | 12 (60) | 0.52 |
Smoking, ever | 6 (30) | 5 (25) | 0.73 |
Lipid profile | |||
 LDL (mg/dl) | 91 ± 26 | 84 ± 20 | 0.44 |
 TG (mg/dl) | 152 ± 92 | 151 ± 81 | 0.83 |
 HDL (mg/dl) | 46 ± 14 | 40 ± 10 | 0.17 |
 TG/HDL | 3.6 ± 2.1 | 3.7 ± 2.1 | 0.73 |
Glycemic marker | |||
 HbA1c (%) | 7.2 ± 0.6 | 7.4 ± 1.1 | 0.51 |
 FBS (mg/dl) | 144 ± 41 | 136 ± 24 | 0.48 |
 HOMA-IR | 2.6 ± 1.9 | 2.5 ± 1.8 | 0.79 |
 iHOMA 2%S | 113 ± 94 | 134 ± 75 | 0.52 |
 Keton body (μmol/l) | 126 ± 116 | 120 ± 105 |  |
Adipose-associated marker | |||
 EAT volume (cm3) | 115 ± 22 | 108 ± 25 | 0.38 |
 TNF-α (pg/ml) | 2.4 ± 0.7 | 2.2 ± 0.7 | 0.78 |
 PAI-1 (ng/ml) | 42.2 ± 16.1 | 45.7 ± 14.6 | 0.41 |
 BNP (pg/ml) | 82 ± 88 | 102 ± 129 | 0.62 |
 Alb/Cre ratio (mg/g CRE) | 21 ± 39 | 38 ± 68 | 0.50 |